# Belantamab mafodotin

Belantamab mafodotin (Blenrep, GlaxoSmithKline Trading Services Limited) has 2 EU-approved indications in 1 tumour type.

## Approved indications

### Multiple myeloma

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | + bortezomib and dexamethasone | 2nd line | After at least one prior therapy; Relapsed or refractory |
| None | + pomalidomide and dexamethasone | 2nd line | After at least one prior therapy including lenalidomide; Relapsed or refractory |

## Products

### Blenrep

- Company: GlaxoSmithKline Trading Services Limited
- Target: BCMA-directed antibody-drug conjugate
- Class: Other monoclonal antibodies and antibody drug conjugates
- ATC: L01FX15
- EU approval: 23 Jul 2025
- Label revised: 26 Aug 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/blenrep-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep

Mechanism (SmPC section 5.1): Binds to cell surface BCMA and internalises to release mcMMAF, disrupting microtubules to cause apoptosis, while also recruiting immune effector cells to kill tumour cells.

## Label wording

- **Belantamab mafodotin** (Blenrep), Multiple myeloma, 2nd line: “in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy” [SmPC](https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf)
- **Belantamab mafodotin** (Blenrep), Multiple myeloma, 2nd line: “in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/belantamab-mafodotin